

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Zoom webinar.**

Thursday, March 16, 2023  
1:00 P.M. to 4:00 P.M. (Eastern)

**Access Information**

Smartphone/Web	Dial-In
<a href="https://magellanhealth.zoom.us/j/92741045029">https://magellanhealth.zoom.us/j/92741045029</a> Webinar ID: 927 4104 5029 Password: 742371	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 927 4104 5029 Passcode: 742371

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of November 2022 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Amvuttra™ (Non-PDL Class)
    - ii. Relyvrio™ (Non-PDL Class)
    - iii. Rolvedon™ (Colony Stimulating Factors)
    - iv. Sunlenca (Antiretrovirals: HIV/AIDS)
- V. Therapeutic Classes with Recommended Changes**
  - a. Antibiotics: Cephalosporins 1st Generation
  - b. Antiretrovirals: HIV/AIDS
  - c. Immunomodulators, Asthma
  - d. Intranasal Antihistamines and Anticholinergics
  - e. Self-Injectable Epinephrine
- VI. Consent Agenda**
  - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Antibiotics: Cephalosporins 2nd Generation</li> <li>• Antibiotics: Cephalosporins 3rd Generation</li> <li>• Antibiotics: Inhaled</li> <li>• Antibiotics: Vaginal</li> <li>• Antibiotics: Gastrointestinal (GI)</li> <li>• Antibiotics: Macrolides/Ketolides</li> <li>• Antibiotics: Oxazolidinones</li> <li>• Antibiotics: Penicillins</li> <li>• Antibiotics: Pleuromutilins</li> <li>• Antibiotics: Quinolones</li> <li>• Antibiotics: Sulfonamides, Folate Antagonists</li> <li>• Antibiotics: Tetracyclines</li> <li>• Antifungals: Oral</li> <li>• Anti-Infectives: Hepatitis B.</li> </ul>	<ul style="list-style-type: none"> <li>• Antivirals: Herpes</li> <li>• Antivirals: Influenza</li> <li>• Beta Agonists: Combination Products</li> <li>• COPD Agents</li> <li>• Hepatitis C: Direct-Acting Antiviral Agents</li> <li>• Hepatitis C: Interferons</li> <li>• Hepatitis C: Ribavirins</li> <li>• Inhaled Corticosteroids</li> <li>• Intranasal Corticosteroids</li> <li>• Leukotriene Modifiers</li> <li>• Long-Acting Beta2 Adrenergic Agonists</li> <li>• Minimally Sedating Antihistamines</li> <li>• Short-Acting Beta2 Adrenergic Agonists</li> </ul>
---	---

**VII. Adjournment**

a. Schedule of Upcoming Meetings

i. **May 18, 2023**

ii. **July 20, 2023**

iii. **September 21, 2023**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.